EGFR expression
|
Nasopharyngeal Carcinoma
|
EGFR expression
|
Nasopharyngeal Carcinoma
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks (NewC3)
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks - (New C3)
|
EGFR expression
|
SCCHN
|
EGFR expression
|
SCCHN
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks (NewC3)
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks - (New C3)
|
EGFR expression
|
Lung Non-Small Cell Squamous Cancer
|
EGFR expression
|
Lung Non-Small Cell Squamous Cancer
|
necitumumab Sensitive: A1 - Approval
|
necitumumab Sensitive: A1 - Approval
|
EGFR expression
|
CRC
|
EGFR expression
|
CRC
|
cetuximab Sensitive: A1 - Approval
|
cetuximab Sensitive: A1 - Approval
|
EGFR expression
|
Chordoma
|
EGFR expression
|
Chordoma
|
lapatinib Sensitive: A2 - Guideline
|
lapatinib Sensitive: A2 - Guideline
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
erlotinib + ramucirumab Sensitive: A2 - Guideline
|
erlotinib + ramucirumab Sensitive: A2 - Guideline
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
erlotinib Sensitive: B - Late Trials
|
erlotinib Sensitive: B - Late Trials
|
EGFR expression
|
CRC
|
EGFR expression
|
CRC
|
panitumumab Sensitive: B - Late Trials
|
panitumumab Sensitive: B - Late Trials
|
EGFR expression
|
HER2 Positive Breast Cancer
|
EGFR expression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: B - Late Trials
|
ado-trastuzumab emtansine Sensitive: B - Late Trials
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
gefitinib Sensitive: B - Late Trials
|
gefitinib Sensitive: B - Late Trials
|
EGFR expression
|
SCCHN
|
EGFR expression
|
SCCHN
|
cetuximab Sensitive: C1 - Off-label
|
cetuximab Sensitive: C1 - Off-label
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
EGFR expression
|
Ovarian Cancer
|
EGFR expression
|
Ovarian Cancer
|
gefitinib Resistant: C3 – Early Trials
|
gefitinib Resistant: C3 – Early Trials
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
sintilimab Sensitive: C3 – Early Trials
|
sintilimab Sensitive: C3 – Early Trials
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
EGFR expression
|
Pancreatic Adenocarcinoma
|
EGFR expression
|
Pancreatic Adenocarcinoma
|
trastuzumab + erlotinib Sensitive: C3 – Early Trials
|
trastuzumab + erlotinib Sensitive: C3 – Early Trials
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
osimertinib Sensitive: C3 – Early Trials
|
osimertinib Sensitive: C3 – Early Trials
|
EGFR expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
gefitinib Sensitive: C3 – Early Trials
|
gefitinib Sensitive: C3 – Early Trials
|
EGFR expression
|
LUAD
|
EGFR expression
|
LUAD
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
anlotinib + APL-502 Sensitive: C3 – Early Trials
|
anlotinib + APL-502 Sensitive: C3 – Early Trials
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
cetuximab + afatinib Resistant: C3 – Early Trials
|
cetuximab + afatinib Resistant: C3 – Early Trials
|
EGFR expression
|
Triple Negative Breast Cancer
|
EGFR expression
|
Triple Negative Breast Cancer
|
lapatinib Sensitive: C3 – Early Trials
|
lapatinib Sensitive: C3 – Early Trials
|
EGFR expression
|
LUAD
|
EGFR expression
|
LUAD
|
afatinib Sensitive: C4 – Case Studies
|
afatinib Sensitive: C4 – Case Studies
|
EGFR expression
|
GBM
|
EGFR expression
|
GBM
|
paclitaxel Sensitive: D – Preclinical
|
paclitaxel Sensitive: D – Preclinical
|
EGFR expression
|
GBM
|
EGFR expression
|
GBM
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|
EGFR expression
|
Glioma
|
EGFR expression
|
Glioma
|
gefitinib Sensitive: D – Preclinical
|
gefitinib Sensitive: D – Preclinical
|
EGFR expression
|
SCCHN
|
EGFR expression
|
SCCHN
|
vandetanib Sensitive: D – Preclinical
|
vandetanib Sensitive: D – Preclinical
|
EGFR expression
|
Pancreatic Cancer
|
EGFR expression
|
Pancreatic Cancer
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
EGFR expression
|
Triple Negative Breast Cancer
|
EGFR expression
|
Triple Negative Breast Cancer
|
AFM24 Sensitive: D – Preclinical
|
AFM24 Sensitive: D – Preclinical
|
EGFR expression
|
SCCHN
|
EGFR expression
|
SCCHN
|
cetuximab + CYNK-101 Sensitive: D – Preclinical
|
cetuximab + CYNK-101 Sensitive: D – Preclinical
|
EGFR expression
|
NSCLC
|
EGFR expression
|
NSCLC
|
cetuximab + CYNK-101 Sensitive: D – Preclinical
|
cetuximab + CYNK-101 Sensitive: D – Preclinical
|
EGFR expression
|
Triple Negative Breast Cancer
|
EGFR expression
|
Triple Negative Breast Cancer
|
LR004-VC-MMAE Sensitive: D – Preclinical
|
LR004-VC-MMAE Sensitive: D – Preclinical
|